The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin. / Rasmussen, Andreas Rosén; Viby, Niels-Erik; Hare, Kristine Juul; Hartmann, Bolette; Thim, Lars; Holst, Jens Juul; Poulsen, Steen Seier.
In: Digestive Diseases and Sciences, Vol. 55, No. 10, 01.10.2010, p. 2785-96.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin
AU - Rasmussen, Andreas Rosén
AU - Viby, Niels-Erik
AU - Hare, Kristine Juul
AU - Hartmann, Bolette
AU - Thim, Lars
AU - Holst, Jens Juul
AU - Poulsen, Steen Seier
PY - 2010/10/1
Y1 - 2010/10/1
N2 - Erlotinib, an epidermal-growth-factor receptor inhibitor, belongs to a new generation of targeted cancer therapeutics. Gastrointestinal side-effects are common and have been markedly aggravated when erlotinib is combined with cytostatics. We examined the effects of erlotinib alone and combined with the cytostatic, cisplatin, on the gastrointestinal tract and examined whether glucagon-like peptide-2 (GLP-2), an intestinal hormone with potent intestinotrophic properties, might counteract the possible damaging effects of the treatments.
AB - Erlotinib, an epidermal-growth-factor receptor inhibitor, belongs to a new generation of targeted cancer therapeutics. Gastrointestinal side-effects are common and have been markedly aggravated when erlotinib is combined with cytostatics. We examined the effects of erlotinib alone and combined with the cytostatic, cisplatin, on the gastrointestinal tract and examined whether glucagon-like peptide-2 (GLP-2), an intestinal hormone with potent intestinotrophic properties, might counteract the possible damaging effects of the treatments.
KW - Animals
KW - Antineoplastic Agents
KW - Atrophy
KW - Body Weight
KW - Cisplatin
KW - Dose-Response Relationship, Drug
KW - Drug Interactions
KW - Female
KW - Gastroenteritis
KW - Gastrointestinal Tract
KW - Glucagon-Like Peptide 2
KW - Mice
KW - Mice, Inbred Strains
KW - Protein Kinase Inhibitors
KW - Quinazolines
U2 - 10.1007/s10620-009-1104-x
DO - 10.1007/s10620-009-1104-x
M3 - Journal article
C2 - 20112065
VL - 55
SP - 2785
EP - 2796
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
SN - 0163-2116
IS - 10
ER -
ID: 33792663